1. Home
  2. KYMR vs UE Comparison

KYMR vs UE Comparison

Compare KYMR & UE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KYMR
  • UE
  • Stock Information
  • Founded
  • KYMR 2015
  • UE 2014
  • Country
  • KYMR United States
  • UE United States
  • Employees
  • KYMR N/A
  • UE N/A
  • Industry
  • KYMR Medicinal Chemicals and Botanical Products
  • UE Real Estate
  • Sector
  • KYMR Health Care
  • UE Finance
  • Exchange
  • KYMR Nasdaq
  • UE Nasdaq
  • Market Cap
  • KYMR 3.1B
  • UE 2.5B
  • IPO Year
  • KYMR 2020
  • UE N/A
  • Fundamental
  • Price
  • KYMR $43.51
  • UE $21.21
  • Analyst Decision
  • KYMR Strong Buy
  • UE Buy
  • Analyst Count
  • KYMR 15
  • UE 2
  • Target Price
  • KYMR $58.53
  • UE $22.50
  • AVG Volume (30 Days)
  • KYMR 722.6K
  • UE 1.1M
  • Earning Date
  • KYMR 10-30-2025
  • UE 10-29-2025
  • Dividend Yield
  • KYMR N/A
  • UE 3.60%
  • EPS Growth
  • KYMR N/A
  • UE N/A
  • EPS
  • KYMR N/A
  • UE 0.84
  • Revenue
  • KYMR $44,711,000.00
  • UE $461,043,000.00
  • Revenue This Year
  • KYMR $58.45
  • UE $6.41
  • Revenue Next Year
  • KYMR N/A
  • UE $4.02
  • P/E Ratio
  • KYMR N/A
  • UE $25.03
  • Revenue Growth
  • KYMR N/A
  • UE 8.59
  • 52 Week Low
  • KYMR $19.45
  • UE $15.66
  • 52 Week High
  • KYMR $53.27
  • UE $23.85
  • Technical
  • Relative Strength Index (RSI)
  • KYMR 53.28
  • UE 66.41
  • Support Level
  • KYMR $39.84
  • UE $20.32
  • Resistance Level
  • KYMR $43.43
  • UE $20.34
  • Average True Range (ATR)
  • KYMR 2.03
  • UE 0.43
  • MACD
  • KYMR 0.15
  • UE 0.07
  • Stochastic Oscillator
  • KYMR 78.76
  • UE 85.93

About KYMR Kymera Therapeutics Inc.

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.

About UE Urban Edge Properties of Beneficial Interest

Urban Edge Properties is a real estate investment trust principally focused on the management and development of retail real estate properties in urban communities in the U.S. Having originally been created to hold the majority of Vornado Realty Trust's shopping center businesses, Urban Edge's asset portfolio is mostly composed of shopping centers and malls in terms of total square footage. The company's holdings include necessity and convenience-oriented retailers, such as department stores, grocers, health clubs, and restaurants. Urban Edge's properties are mainly located in the New York City metropolitan region and within the DC to Boston corridor. The company generates nearly all of its revenue through the collection of rent from a large number of tenants.

Share on Social Networks: